Association of primary (1°) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor (αEGFR) therapy.

Michael Sangmin Lee(University of North Carolina at Chapel Hill), Scott Kopetz(The University of Texas MD Anderson Cancer Center), Bradley M. Broom(The University of Texas MD Anderson Cancer Center), Dipen M. Maru(The University of Texas MD Anderson Cancer Center), David G. Menter(The University of Texas MD Anderson Cancer Center), Ganiraju C. Manyam(The University of Texas MD Anderson Cancer Center), Stanley R. Hamilton(City of Hope), Shailesh Advani(The University of Texas MD Anderson Cancer Center), Zhi-Qin Jiang(The University of Texas MD Anderson Cancer Center), Michael J. Overman(The University of Texas MD Anderson Cancer Center), Jeffrey S. Morris(The University of Texas MD Anderson Cancer Center), Cathy Eng(Vanderbilt University)
Journal of Clinical Oncology
May 20, 2016
Cited by 26


Related Papers